Cargando…
Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy
Autores principales: | Lee, Brittany M., Summers, Corinne, Chisholm, Karen M., Bohling, Sandra D., Leger, Kasey J., Gardner, Rebecca, Annesley, Colleen, Lamble, Adam J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279539/ https://www.ncbi.nlm.nih.gov/pubmed/36763522 http://dx.doi.org/10.1182/bloodadvances.2022009480 |
Ejemplares similares
-
Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023) -
Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023) -
Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020) -
Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer
por: Li, Lingling, et al.
Publicado: (2022) -
Lineage Switching in Acute Leukemias: A Consequence of Stem Cell Plasticity?
por: Dorantes-Acosta, Elisa, et al.
Publicado: (2012)